Plant-Based Vaccines, Antibodies & Biologics

5-7 June 2017, NAU Sao Rafael Atlantico Hotel, Albufeira, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

Join the conversation on Twitter – #PBVAB2017

Commercial protein drugs, which include recombinant monoclonal antibodies, subunit vaccines, immune modulators, and human enzymes, will likely exceed $100billion in market size within the next two years. A component of this extraordinary growth is the availability of new technologies to speed the time to market of new biologics, and to create improved versions of existing drugs. Among the new developments is the emerging use of green plants for recombinant protein production due to advantages over yeast, cultured mammalian or insect cells, or other living systems. It is becoming increasingly evident that:

  • Government regulatory agencies have accepted plant production in new drug approval and licensure
  • Monoclonal antibody production in plants offers rapid production advantages in comparison to mammalian cells, with at least equivalent product safety, purity and potency
  • Metabolic engineering of tobacco as a host for protein production is advancing rapidly to allow highly uniform drug products, including post-translational modifications similar to those of human cells
  • Plant-based manufacturing platforms hold major promise for next generation biogenerics (or biobetters with improved pharmacokinetic properties)
  • Plant-made subunit vaccines are in the pipeline for multiple infectious diseases
  • Ongoing corporate drug development at commercial scale is providing data to accurately determine the potential to reduce manufacturing cost of protein drugs under cGMP requirements using plant protein expression as the starting point

PBVAB 2017 is the seventh meeting in this important and successful series. PBVAB 2017 will offer an international forum to review the current state of research in plant protein expression systems, down-stream processing technology, the pipeline of products now in development (including vaccines, monoclonal antibodies, and human enzymes), and efforts in using these technologies in areas beyond human health (including disease prevention in animals and aquaculture).

PBVAB 2017 will aim to attract an international audience of researchers, clinicians, and representatives for academia, industry and government/regulatory/public health organizations. Representatives for the human, veterinary, plant communities with an interest in vaccinology, immunology, biotechnology issues in relation to plant-based systems will find PBVAB 2017 of value. PBVAB 2017 will seek to develop the synergy between the human and veterinary medical/immunological/plant biotechnology communities by focusing on the immunology, vaccinology, delivery, adjuvants, and efficacy of plant based proteins.

PBVAB 2017 will aim to emphasise the take-off of the commercialisation of plant-based biologic products, the requirement for more academic based research to respond to the  question: Where is the pipeline of products going to come from and what have we learned on the decision-making processes for that product pipeline?

Scientific Advisory Panel

Conference Chairman:
Julian Ma (St. George’s University of London, London, UK)

Diego Orzaez (CSIC, University of Valencia, Spain)
George Lomonossoff (John Innes Centre, Norwich, UK)
Kevin Whaley (Mapp Biopharmaceutical Inc., USA)
Rainer Fischer (RWTH Aachen, Germany)
Pascal Drake (St. George’s University of London, London, UK)
Ed Rybicki (University of Capetown, South Africa)
Yuri Gleba (NOMAD Bioscience, Munich, Germany)
Hugh Haydon (Kentucky BioProcessing, Owensboro, Kentucky, USA)
Charles Arntzen (Arizona State University, Tempe, Arizona, USA)
Marc-Andre D’Aoust (Medicago Inc., Quebec, Canada)
Ann Depicker (University of Ghent, Ghent, Belgium)
Yoseph Shaaltiel (Protalix Biotherapeutics, Carmiel, Israel)
Takeshi Matsumura (AIST, Japan)
Marcos da Silva Freire (Bio-Manguinhos/Fiocruz, Brazil)
Andres Wigdorovitz (INTA, Buenos Aires, Argentina)
Sun Lee (NEXGEN Biotechnologies Inc., Seoul, South Korea)
Victor Klimyuk (ICON Genetics GmbH, Halle, Germany)
Robert Erwin (iBio Inc., Newark, Delaware, USA)

Conference Sessions/Topics

Main Sessions:

  • Challenges to Commercialisation
  • Product Pipelines
  • Vaccines
  • Antibodies
  • Adjuvants
  • Biologics
  • Expression Systems
  • Pre-clinical & Clinical Evaluations
  • Regulatory & Socio-ethical Issues

The PBVAB 2017 conference will focus on the following main topics:

  • Global need for vaccines and antibodies that can address large, cost-sensitive markets
  • Plant-based protein expression systems
  • Molecular pharming issues
  • Plant viral vector expression systems
  • Plant-derived antigens & adjuvants
  • Production and scale-up
  • Plant-derived antibodies with infectious agent targets/new targets
  • Purification and GHP manufacture
  • Regulatory control
  • Biofuels
  • Containment strategies (physical/genetic)
  • Delivery systems
  • Biofortification
  • Preventing pathogen transmission across mucosal surfaces
  • Downstream processing issues
  • Clinical trials
  • Biosafety/regulatory/public health issues

Whilst this list is not exhaustive it does give an indication of the main focus of PBVAB 2017 and the areas where abstract submissions for both oral and poster presentation are being encouraged by the Scientific Advisory Panel.

 

PBVAB 2017 Delegates

Login details will be supplied after you have registered for the event.


PBVAB 2017 Sponsors

  • Plant Transformation Technologies
  • Ilvo
  • iBio
  • Icon Genetics
  • Fraunhofer IME
  • Nomad
  • Intrucept Biomedicine
  • Angany Genetics
  • Root Lines Technology
  • Mapp Biopharmaceutical
  • Planet Biotechnology
  • Medicago
  • VisMederi
  • Aldevron
  • The International Society for Plant Molecular Farming
  • John Innes Centre
  • Biovaxx
  • Conviron
  • Plant Form
  • NexGen
  • Greenovation
  • Kentucky Bioprocessing
  • Owensboro Cancer Research Program
  • Fraunhofer USA
  • BioApp
  • Molecular Farming
  • Protalix Biotherapeutics
  • Epso

PBVAB 2017 Downloads

PBVAB 2017 Leaflet

PBVAB 2017 Mailing List

Name
E-mail Address
What is 3+2-1?